Prior research indicates that the progression of visceral amyloidosis secondary to skin inflammation can be mitigated by inhibiting IL-17A during the early and mild phase of the disease [8], as well as through the application of JAK inhibitors [7]. This evidence concerns the gene IL17A and dermatitis.